933041-13-5

Basic information

• Product Name: 4-BroMo-6-chloropyridazin-3(2H)-one
• Synonyms: 4-BroMo-6-chloropyridazin-3(2H)-one;4-BroMo-6-chloro-2H-pyridazin-3-one;5-bromo-3-chloro-1H-pyridazin-6-one;4-bromo-6-chloro-3(2H)-Pyridazinone;4-Bromo-6-chloropyridazin-3(2H)
• CAS NO: 933041-13-5
• Molecular Formula: C4H2BrClN2O
• Molecular Weight: 209.42848
• Mol File: 933041-13-5.mol
• Article Data: 11

Chemical Properties

• Melting Point: 220-222 °C(Solv: ethanol (64-17-5); water (7732-18-5))
• Appearance: /
• Density: 2.16±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 8.13±0.60(Predicted)
• CAS DataBase Reference: 4-BroMo-6-chloropyridazin-3(2H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BroMo-6-chloropyridazin-3(2H)-one(933041-13-5)
• EPA Substance Registry System: 4-BroMo-6-chloropyridazin-3(2H)-one(933041-13-5)

Safety Data

• Hazardous Substances Data: 933041-13-5(Hazardous Substances Data)

Usage

General Description

4-Bromo-6-chloropyridazin-3(2H)-one, also known by its chemical formula C5H3BrClN2O, is a heterocyclic compound that consists of a pyridazine ring with bromine and chlorine substituents at different positions. It is commonly used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. This chemical compound is also known for its potential biological activities and is being studied for its anti-cancer, anti-inflammatory, and anti-bacterial properties. Additionally, it is used in organic synthesis as a building block for the development of new compounds with diverse applications.

Upstream product

• 446273-59-2 4-bromo-6-chloro-3-pyridazineamine 
• 19064-67-6 3-chloro-6-hydroxypyridazine 
• 19064-67-6 6-chloro-2H-pyridazin-3-one 

Downstream Products

• 1361386-81-3 6-chloro-4-(1-methyl-1H-pyrazol-3-ylamino)pyridazin-3(2H)-one 
• 1346673-30-0 6-chloro-4-(pyrimidin-4-ylamino)pyridazin-3(2H)-one 

Relevant articles and documents

Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic

Direct pharmacological inhibition of RAS has remained elusive, and efforts to target CRAF have been challenging due to the complex nature of RAF signaling, downstream of activated RAS, and the poor overall kinase selectivity of putative RAF inhibitors. Herein, we describe 15 (LXH254, Aversa, R.; et al. Int. Patent WO2014151616A1, 2014), a selective B/C RAF inhibitor, which was developed by focusing on drug-like properties and selectivity. Our previous tool compound, 3 (RAF709; Nishiguchi, G. A.; et al. J. Med. Chem. 2017, 60, 4969), was potent, selective, efficacious, and well tolerated in preclinical models, but the high human intrinsic clearance precluded further development and prompted further investigation of close analogues. A structure-based approach led to a pyridine series with an alcohol side chain that could interact with the DFG loop and significantly improved cell potency. Further mitigation of human intrinsic clearance and time-dependent inhibition led to the discovery of 15. Due to its excellent properties, it was progressed through toxicology studies and is being tested in phase 1 clinical trials.

Histone deacetylase inhibitor taking pyridazinone as mother nucleus structure, and preparation method and applications thereof

The invention discloses a histone deacetylase inhibitor taking pyridazinone as a mother nucleus structure, and a preparation method and applications thereof. The structure of the inhibitor is shown asa formula I; and the compound shown as the formula I has good histone deacetylase inhibitory activity and anti-tumor cell proliferation effects, and can be used for treating cancers. The structure ofthe inhibitor is shown as the formula I.

2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES

Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.